FIELD: biotechnology.
SUBSTANCE: described is a recovered human antibody or an antigen-binding fragment of said antibody, showing binding affinity (KD) of 10 nM or more to one or more strains of each of the clades of influenza B virus of the Yamagata line and influenza B virus of the Victoria line, wherein said antibody or said fragment comprises: (a) a complementarity determining region 1 of a heavy chain (HCDR1), (b) a complementarity determining region 2 of a heavy chain (HCDR2); and (c) complementarity determining heavy chain region 3 (HCDR3), wherein HCDR1/HCDR2/HCDR3 are selected from a group consisting of SEQ ID NO: 31/32/33; 41/42/43; 51/52/53; 61/62/63; 71/72/73; 81/82/83; 91/92/93; 101/102/103; 111/112/113; 121/122/123; 131/132/133; 141/142/143; 151/152/153; 161/162/163; 171/172/173; 181/182/183; 191/192/193; 201/202/203; 211/212/213; 221/222/223; 231/232/233; 241/242/243; 251/252/253; 261/262/263; 271/272/273 and 281/282/283, and (d) complementarity determining light chain region 1 (LCDR1), (e) complementarity determining light chain region 2 (LCDR2); and (f) complementarity determining light chain region 3 (LCDR3), wherein LCDR1/LCDR2/LCDR3 are selected from a group consisting of SEQ ID NO: 34/35/36; 44/45/46; 54/55/56; 64/65/66; 74/75/76; 84/85/86; 94/95/96; 104/105/106; 114/115/16; 124/125/126; 134/135/136; 144/145/146; 154/155/156; 164/165/166; 174/175/176; 184/185/186; 194/195/196; 204/205/206; 214/215/216; 224/225/226; 234/235/236; 244/245/246; 254/255/256; 264/265/266; 274/275/276; and 284/285/286, wherein said antibody or fragment have the influenza virus binding and/or inhibiting property.
EFFECT: invention can be used for effective passive immunization against all strains of influenza A and B.
43 cl, 25 dwg, 6 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INFLUENZA HEMAGGLUTININ COMPOSITIONS WITH HETEROLOGOUS EPITOPES AND/OR ALTERED CLEAVAGE SITES DURING MATURATION | 2017 |
|
RU2769406C2 |
| SELF-ASSEMBLED NANOSTRUCTURED VACCINES | 2019 |
|
RU2811439C2 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| HEMAGLUTININ MUTANTS OF INFLUENZA VIRUS | 2019 |
|
RU2809237C2 |
| HEMAGLUTININ MUTANTS OF THE INFLUENZA VIRUS | 2019 |
|
RU2801708C2 |
| RECOMBINANT VECTORS EXPRESSING AVIAN INFLUENZA VIRUS ANTIGENS AND APPLICATIONS THEREOF | 2017 |
|
RU2761869C2 |
| NEUTRALISING ANTI-INFLUENZA A ANTIBODIES AND USES THEREOF | 2014 |
|
RU2683498C2 |
| NEUTRALIZING ANTIBODIES AGAINST THE INFLUENZA A VIRUS AND WAYS OF THEIR APPLICATION | 2014 |
|
RU2803850C2 |
| INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
